Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

OBJECTIVE: To investigate the efficacy, safety, immunogenicity and pharmacokinetics of biosimilar adalimumab (ADL) PF-06410293 (ADL-PF; adalimumab-afzb) versus EU-sourced reference ADL (ADL-EU) in patients with active rheumatoid arthritis (RA) on longer-term treatment and after being switched from A...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy M, Alvarez, Daniel F, Bock, Amy E, Cronenberger, Carol, Vranic, Ivana, Zhang, Wuyan, Alten, Rieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061859/
https://www.ncbi.nlm.nih.gov/pubmed/33883254
http://dx.doi.org/10.1136/rmdopen-2021-001578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061859/
https://www.ncbi.nlm.nih.gov/pubmed/33883254
http://dx.doi.org/10.1136/rmdopen-2021-001578

Ejemplares similares